ARYA IV (NASDAQ:ARYD) has agreed to mutually terminate its combination with the gene therapy division of biotech firm Amicus (NASDAQ:FOLD).
The news came not from ARYA IV’s end but as a part of Amicus’ quarterly updates and it primarily blamed “unfavorable market conditions affecting IPOs, follow-on financings and SPACs”. Those conditions are real and appear poised to get worse with the latest news out of Eastern Europe, but are also accompanied by news that Amicus’ CEO and COO will both also be moving on.
Whether these departures are a cause or effect of the deal’s fate are purely speculative, but it is possible that there is more than market concerns behind the decision. Nonetheless, neither side will pay breakup fees and ARYA IV has until March 2, 2023 to complete a transaction, which is plenty of time assuming the market is forgiving.
The price performance of biotech de-SPACs had been slipping as seen in SPACInsider’s Full Year 2021 Report, and Amicus itself is down about 31% since the start of the year. More than anything, it could be a sign that we see pressure on more deals struck in better times. Both sides have an easier “out” in blaming market conditions now that one more force majeure has been added to the mix.
The parties originally announced their $242 million combination in September. Headwinds aside, the ARYA team has produced the 9th-best returns (as of today) among serial SPAC teams with an average de-SPAC share price of $11.74, largely thanks to its combination with Cerevel Therapeutics (NASDAQ:CERE), which last closed at $23.50.
Despite a week of general pull-backs in the market, fintech firm Ibotta (NYSE:IBTA) nonetheless took the dive and had a good week debuting via a traditional IPO in the choppy waters. The company, which provides app-based consumer cashback discounts on purchases, priced its IPO at $88, above its proposed range of $76 to $84, and...
At the SPAC of Dawn Happy Friday! SPACInsider has unveiled new presets on SPAC Performance accessible via the Data drop-down to easily sort for the highest and lowest performing active SPACs and de-SPACs. On the de-SPAC side, Vertiv (NYSE:VRT) continues to be well ahead of the pack, logging a 710% return by share price adjusted...
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...